NASDAQ:ACRV Acrivon Therapeutics Q3 2026 Earnings Date & Estimates $1.76 +0.04 (+2.33%) Closing price 10/15/2026 04:00 PM EasternExtended Trading$1.80 +0.03 (+1.99%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Acrivon Therapeutics is estimated to report Q3 2026 earnings on Thursday, November 12, 2026. The conference call is scheduled for November 9, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 12, 2026Conference Call DateNovember 9, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Acrivon Therapeutics in Q3 2026Acrivon Therapeutics is expected to post earnings of -$0.45 per share on revenue of $0.50 million. In the same quarter a year earlier Acrivon Therapeutics reported -$0.47 per share. Acrivon Therapeutics last reported on August 12, 2026, posting -$0.43 per share and beating the -$0.5022 consensus estimate. Acrivon Therapeutics has beaten the consensus EPS estimate in 6 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.45Expected Revenue$0.50 millionPrior-Year EPS-$0.47Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.43 (Beat by +$0.0722)EPS Beat Rate6 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Acrivon Therapeutics Q3 2026 Earnings FAQ When does Acrivon Therapeutics report Q3 2026 earnings? Acrivon Therapeutics (NASDAQ:ACRV) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Acrivon Therapeutics' Q3 2026 earnings call? Acrivon Therapeutics' Q3 2026 earnings conference call is scheduled for Monday, November 9, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Acrivon Therapeutics? Analysts expect Acrivon Therapeutics to post earnings of -$0.45 per share for Q3 2026. How much revenue is Acrivon Therapeutics expected to report? The consensus revenue estimate for Acrivon Therapeutics is $0.50 million for Q3 2026. Acrivon Therapeutics Earnings HeadlinesAcrivon Therapeutics (NASDAQ:ACRV) Upgraded to "Hold" at Wall Street ZenOctober 5, 2026 | americanbankingnews.comAcrivon Therapeutics to Present at the 2026 Cantor Global Healthcare ConferenceSeptember 2, 2026 | globenewswire.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery. | Behind the Markets (Ad)Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business OfficerAugust 31, 2026 | globenewswire.comAcrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data CatalystsAugust 13, 2026 | finance.yahoo.comAcrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 StudyAugust 5, 2026 | globenewswire.comSee More Acrivon Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Acrivon Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Acrivon Therapeutics and other key companies, straight to your email. Email Address About Acrivon TherapeuticsAcrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biopharmaceutical company focused on developing precision oncology medicines for patients with difficult-to-treat cancers. The company uses its Acrivon Predictive Precision Oncology (AP3) platform to identify tumor characteristics that may predict a patient’s response to specific targeted therapies. Acrivon’s lead program is ACR-368, an orally administered small-molecule inhibitor designed to target the checkpoint kinase 1 (CHK1) and WEE1 proteins, which help regulate tumor-cell replication and DNA damage responses. The company is evaluating ACR-368 in selected solid tumors, including ovarian and endometrial cancers, using its OncoSignature approach as a potential biomarker-based companion diagnostic to identify patients most likely to benefit. The company is also advancing additional targeted oncology programs, including ACR-2316, a selective WEE1 inhibitor. Acrivon was founded in 2018 and is headquartered in Watertown, Massachusetts. Its research and clinical development activities are focused on advancing precision treatments for cancer patients in the United States and other major clinical markets.View Acrivon Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
